CDKN2A and pancreatic neoplasm: The authors applied the Pan02 model for their studies, which does not harbor the pancreatic cancer driver mutations Kirsten rat sarcoma viral oncogene homolog (KRAS), tumor protein 53 (TP53), and cyclin-dependent kinase inhibitor 2A (CDKN2A), but a SMAD family member 4 (SMAD4) mutation[10,11].